The litigation centers on claims that Zoetis executives issued false statements about market share and sales growth for its Companion Animal division. According to the complaint, the company failed to disclose that demand for its canine pain treatment, Librela, was declining as veterinarians grew wary of reports linking the drug to neurological complications. Furthermore, the lawsuit asserts that Zoetis lost significant market share for its Simparica Trio, Apoquel, and Cytopoint products to lower-priced or newly launched competitors.

Rosen Law Firm, which is spearheading the action, is urging affected investors to evaluate their legal representation before the court-mandated deadline. While a lawsuit has been filed, no class has been certified, meaning investors are not currently represented by counsel unless they choose to retain one. Those who purchased Zoetis stock during the specified period may be eligible for compensation through a contingency fee arrangement, which requires no out-of-pocket costs from the claimant.